Research programme: SCAP ligands - GlaxoSmithKline

Drug Profile

Research programme: SCAP ligands - GlaxoSmithKline

Alternative Names: GW 300; GW 532; GW 575; GW 707

Latest Information Update: 19 Mar 2007

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class
  • Mechanism of Action LDL receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hyperlipidaemia

Most Recent Events

  • 13 Feb 2002 New profile
  • 13 Feb 2002 Preclinical development for Hyperlipidaemia in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top